PLoS ONE:揭秘驱动黑色素瘤迁移的关键分子机理

2015-04-08 佚名 生物谷

近日,来自Norris Cotton癌症研究中心的研究人员通过研究鉴别出了名为CXCR3分子的一个新的角色,研究者发现该分子可以扮演黑色素瘤转移的关键介导子,相关研究刊登于国际杂志PLoS One上。研究者Mullins表示,我们假设黑色素瘤可以进行感知活动使其周围的环境变得较为恶劣,随后其就可以通过激活一种逃逸机制来产生反应,进而寻找更适于癌细胞繁衍的环境;而本文中我们发现黑色素瘤可以上调趋化因

近日,来自Norris Cotton癌症研究中心的研究人员通过研究鉴别出了名为CXCR3分子的一个新的角色,研究者发现该分子可以扮演黑色素瘤转移的关键介导子,相关研究刊登于国际杂志PLoS One上。

研究者Mullins表示,我们假设黑色素瘤可以进行感知活动使其周围的环境变得较为恶劣,随后其就可以通过激活一种逃逸机制来产生反应,进而寻找更适于癌细胞繁衍的环境;而本文中我们发现黑色素瘤可以上调趋化因子受体CXCR3分子来对压力产生反应,包括营养物或氧气缺乏,随后黑色素瘤细胞就可以利用CXCR3来开启迁移过程,揭示其中的机制或许可以帮助开发新型疗法来干预黑色素瘤,进而帮助改善常规疗法或基于免疫的疗法的疗效。

研究者表示,肿瘤细胞可以在其入侵到局部环境的过程中从原始位点分离出来,进而转移到较远的位点;CXCR3分子对于免疫细胞的迁移起着非常关键的介导作用,研究者同时也鉴别出了CXCR3分子促进黑色素瘤转移的分子机制;截止到目前,许多进行黑色素瘤的研究都仅仅关注到了发生特定突变的一半黑色素瘤,而本文研究中研究者对另外一半没有发生相同突变的黑色素瘤进行了重点研究,这或许为揭示肿瘤转移的新型机体提供了新的帮助。

Brinckerhoff教授表示,揭示黑色素瘤利用CXCR3分子诱导肿瘤转移的分子机制或可帮助我们进行特殊的药理学研究及免疫靶向研究,从而为后期开发潜在的干预措施来减少或抑制黑色素瘤的转移提供思路。

未来研究中,研究小组希望继续进行研究来揭示调节黑色素瘤中CXCR3表达的机制,目的是为了理解环境压力或免疫压力如何诱导CXCR3分子的表达。

原始出处:

Molly H. Jenkins, Constance E. Brinckerhoff, David W. Mullins.CXCR3 Signaling in BRAFWT Melanoma Increases IL-8 Expression and Tumorigenicity[J].PLoS One. 2015 Mar 23;10(3):e0121140. doi: 10.1371/journal.pone.0121140. eCollection 2015.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1922340, encodeId=862719223406a, content=<a href='/topic/show?id=768d316206c' target=_blank style='color:#2F92EE;'>#分子机理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31620, encryptionId=768d316206c, topicName=分子机理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Sat Aug 22 05:09:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680277, encodeId=71b216802e7ca, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Jun 06 05:09:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789653, encodeId=a0bb1e89653f8, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jan 08 17:09:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1640901, encodeId=4145164090126, content=<a href='/topic/show?id=7c99939e3fd' target=_blank style='color:#2F92EE;'>#迁移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93973, encryptionId=7c99939e3fd, topicName=迁移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d37c22750496, createdName=ms8888626721583891, createdTime=Thu Mar 17 08:09:00 CST 2016, time=2016-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558692, encodeId=7e3715586922e, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Apr 10 04:09:00 CST 2015, time=2015-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564701, encodeId=97951564e0145, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Apr 10 04:09:00 CST 2015, time=2015-04-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1922340, encodeId=862719223406a, content=<a href='/topic/show?id=768d316206c' target=_blank style='color:#2F92EE;'>#分子机理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31620, encryptionId=768d316206c, topicName=分子机理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Sat Aug 22 05:09:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680277, encodeId=71b216802e7ca, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Jun 06 05:09:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789653, encodeId=a0bb1e89653f8, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jan 08 17:09:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1640901, encodeId=4145164090126, content=<a href='/topic/show?id=7c99939e3fd' target=_blank style='color:#2F92EE;'>#迁移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93973, encryptionId=7c99939e3fd, topicName=迁移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d37c22750496, createdName=ms8888626721583891, createdTime=Thu Mar 17 08:09:00 CST 2016, time=2016-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558692, encodeId=7e3715586922e, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Apr 10 04:09:00 CST 2015, time=2015-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564701, encodeId=97951564e0145, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Apr 10 04:09:00 CST 2015, time=2015-04-10, status=1, ipAttribution=)]
    2015-06-06 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1922340, encodeId=862719223406a, content=<a href='/topic/show?id=768d316206c' target=_blank style='color:#2F92EE;'>#分子机理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31620, encryptionId=768d316206c, topicName=分子机理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Sat Aug 22 05:09:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680277, encodeId=71b216802e7ca, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Jun 06 05:09:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789653, encodeId=a0bb1e89653f8, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jan 08 17:09:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1640901, encodeId=4145164090126, content=<a href='/topic/show?id=7c99939e3fd' target=_blank style='color:#2F92EE;'>#迁移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93973, encryptionId=7c99939e3fd, topicName=迁移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d37c22750496, createdName=ms8888626721583891, createdTime=Thu Mar 17 08:09:00 CST 2016, time=2016-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558692, encodeId=7e3715586922e, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Apr 10 04:09:00 CST 2015, time=2015-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564701, encodeId=97951564e0145, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Apr 10 04:09:00 CST 2015, time=2015-04-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1922340, encodeId=862719223406a, content=<a href='/topic/show?id=768d316206c' target=_blank style='color:#2F92EE;'>#分子机理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31620, encryptionId=768d316206c, topicName=分子机理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Sat Aug 22 05:09:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680277, encodeId=71b216802e7ca, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Jun 06 05:09:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789653, encodeId=a0bb1e89653f8, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jan 08 17:09:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1640901, encodeId=4145164090126, content=<a href='/topic/show?id=7c99939e3fd' target=_blank style='color:#2F92EE;'>#迁移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93973, encryptionId=7c99939e3fd, topicName=迁移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d37c22750496, createdName=ms8888626721583891, createdTime=Thu Mar 17 08:09:00 CST 2016, time=2016-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558692, encodeId=7e3715586922e, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Apr 10 04:09:00 CST 2015, time=2015-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564701, encodeId=97951564e0145, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Apr 10 04:09:00 CST 2015, time=2015-04-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1922340, encodeId=862719223406a, content=<a href='/topic/show?id=768d316206c' target=_blank style='color:#2F92EE;'>#分子机理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31620, encryptionId=768d316206c, topicName=分子机理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Sat Aug 22 05:09:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680277, encodeId=71b216802e7ca, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Jun 06 05:09:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789653, encodeId=a0bb1e89653f8, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jan 08 17:09:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1640901, encodeId=4145164090126, content=<a href='/topic/show?id=7c99939e3fd' target=_blank style='color:#2F92EE;'>#迁移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93973, encryptionId=7c99939e3fd, topicName=迁移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d37c22750496, createdName=ms8888626721583891, createdTime=Thu Mar 17 08:09:00 CST 2016, time=2016-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558692, encodeId=7e3715586922e, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Apr 10 04:09:00 CST 2015, time=2015-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564701, encodeId=97951564e0145, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Apr 10 04:09:00 CST 2015, time=2015-04-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1922340, encodeId=862719223406a, content=<a href='/topic/show?id=768d316206c' target=_blank style='color:#2F92EE;'>#分子机理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31620, encryptionId=768d316206c, topicName=分子机理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Sat Aug 22 05:09:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680277, encodeId=71b216802e7ca, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Jun 06 05:09:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789653, encodeId=a0bb1e89653f8, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jan 08 17:09:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1640901, encodeId=4145164090126, content=<a href='/topic/show?id=7c99939e3fd' target=_blank style='color:#2F92EE;'>#迁移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93973, encryptionId=7c99939e3fd, topicName=迁移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d37c22750496, createdName=ms8888626721583891, createdTime=Thu Mar 17 08:09:00 CST 2016, time=2016-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558692, encodeId=7e3715586922e, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Apr 10 04:09:00 CST 2015, time=2015-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564701, encodeId=97951564e0145, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Apr 10 04:09:00 CST 2015, time=2015-04-10, status=1, ipAttribution=)]

相关资讯

郭军教授:2014年黑色素瘤进展

近年来,人类在征服癌症的道路上取得了辉煌的进步。在所有的恶性肿瘤治疗中,黑色素瘤治疗的进步尤为令人瞩目,特别是抗PD-1抗体在黑色素瘤治疗中所取得的成功,很可能会在未来的几年中彻底影响并改变其它多种恶性肿瘤的治疗模式。黑色素瘤,这一十年前似乎还“无药可治”的恶性肿瘤,在免疫靶向治疗和个体化靶向治疗日新月异的今天,似乎我们已经依稀看到扼住这条恶龙喉咙的一天即将到来。 免疫靶向治疗前景光明 抗

Clin Cancer Res:黑色素瘤靶向治疗失败?巨噬细胞作祟!

在过去的几年中,以药物直接影响参与癌症的进展的特定基因和蛋白质为主要特征的靶向疗法,已获批准应用于各种癌症的治疗,包括被称为最致命皮肤癌的黑色素瘤。现在, Wistar研究所的研究人员发现了黑色素瘤对此类药物耐药的一个新途径,而对这种现象认识可能会形成一个新的黑色素瘤靶向目标或新治疗方法的设计方向。该项研究发表在最新一期的Clinical Cancer Research杂志上。靶向药物的攻击对象是

Clin Cancer Res:尼罗替尼对KIT突变的黑色素瘤的II期临床研究

目的:尽管采用酪氨酸激酶抑制剂伊马替尼作用于KIT突变的黑色素瘤能达到持续的响应,但选择性抑制剂伊马替尼的疗效以及这类药物对脑转移瘤的活性是未知的。实验设计:我们将有KIT突变或扩增的黑色素瘤患者分成两组,采用尼罗替尼400毫克BID进行 II期临床研究:A)先前用KIT抑制剂难治的或不能耐受的患者;和b)脑转移瘤的患者。主要终点是4个月的疾病控制率。次要终点包括响应率,疾病进展期和总生存期。西蒙

AJHSP:治疗转移性皮肤黑色素瘤新型抑制剂---曲美替尼

目的: 对曲美替尼治疗转移性黑色素瘤在药理学、药代动力学、临床疗效、安全性、临床管理、成本等方面进行了总结。 摘要:约40-60%的恶性黑素瘤有BRAF600基因密码子的突变基因,其导致蛋白激酶(MAPK)通道的激活。曲美替尼是首个细胞外信号的MEK抑制剂,靶标是在对肿瘤细胞增殖,存活,入侵,肿瘤血管生成,逃避凋亡中起关键作用的MEK激酶。美国食品药品监督管理局批准曲美替尼用于BRAF基因V60

STM:治疗黑色素瘤,三合一效果更佳!

来自加州大学洛杉矶分校的研究人员的一项新研究结果发现,开创性的三联治疗在晚期黑色素瘤的控制方面获得更有效的疾病控制率。该法的有效率优于过去一直沿用的BRAF + MEK抑制剂或BRAF抑制剂+免疫治疗组合,并且能够增加免疫应答强度以及减少药物的毒副作用。这项研究结果发表在最新一期的Science Translational Medicine杂志上。靶向药物的攻击对象是发生突变的癌细胞而对健康组织的

JNCI:两microRNA力挽黑色素瘤转移之狂澜

来自于纽约大学Langone医学中心及其Laura和Isaac Perlmutter肿瘤中心的研究人员,在被认为是迄今最大的对早期黑色素瘤细胞信号分子表观遗传分析的研究中,确定了在肿瘤中两个小的非编码基因材料与关键癌细胞的扩散的停滞相关,本质上影响着肿瘤的生物学命运。 在2月11日在线发表在Journal of the National Cancer Institute杂志上的一篇研究报告中